430 related articles for article (PubMed ID: 30702990)
1. Antithrombotic Agents.
Chan NC; Weitz JI
Circ Res; 2019 Feb; 124(3):426-436. PubMed ID: 30702990
[TBL] [Abstract][Full Text] [Related]
2. Advances in Antithrombotic Therapy.
Weitz JI; Chan NC
Arterioscler Thromb Vasc Biol; 2019 Jan; 39(1):7-12. PubMed ID: 30580558
[TBL] [Abstract][Full Text] [Related]
3. Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
Coppens M; Weitz JI; Eikelboom JWA
Circ Res; 2019 Feb; 124(3):416-425. PubMed ID: 30702997
[TBL] [Abstract][Full Text] [Related]
4. Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome.
Weitz JI
Thromb Haemost; 2014 Nov; 112(5):924-31. PubMed ID: 25030773
[TBL] [Abstract][Full Text] [Related]
5. Individualized antithrombotic therapy.
Lüscher TF; Steffel J
Hamostaseologie; 2016; 36(1):26-32. PubMed ID: 25597592
[TBL] [Abstract][Full Text] [Related]
6. Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence.
Weitz JI; Angiolillo DJ; Geisler T; Heitmeier S
Thromb Haemost; 2020 Aug; 120(8):1147-1158. PubMed ID: 32594508
[TBL] [Abstract][Full Text] [Related]
7. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M
JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085
[TBL] [Abstract][Full Text] [Related]
8. Factors IX, XI, and XII: potential therapeutic targets for anticoagulant therapy in atherothrombosis.
Rai V; Balters MW; Agrawal DK
Rev Cardiovasc Med; 2019 Dec; 20(4):245-253. PubMed ID: 31912715
[TBL] [Abstract][Full Text] [Related]
9. Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin.
Eikelboom JW; Bosch JJ; Connolly SJ; Shestakovska O; Dagenais GR; Hart RG; Leong DP; O'Donnell M; Fox KAA; Bhatt DL; Cairns JA; Tasto C; Berkowitz SD; Cook Bruns N; Muehlhofer E; Diaz R; Maggioni AP; Yusuf S
J Am Coll Cardiol; 2019 Sep; 74(12):1519-1528. PubMed ID: 31537259
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy.
Barra ME; Fanikos J; Connors JM; Sylvester KW; Piazza G; Goldhaber SZ
Am J Med; 2016 Nov; 129(11):1198-1204. PubMed ID: 27341955
[TBL] [Abstract][Full Text] [Related]
11. Direct oral anticoagulants: An update.
Franco Moreno AI; Martín Díaz RM; García Navarro MJ
Med Clin (Barc); 2018 Sep; 151(5):198-206. PubMed ID: 29295790
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial.
Korjian S; Braunwald E; Daaboul Y; Verheugt F; Bode C; Tendera M; Jain P; Plotnikov A; Burton P; Gibson CM
Eur Heart J Acute Cardiovasc Care; 2019 Mar; 8(2):186-193. PubMed ID: 29249166
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotics in atrial fibrillation and coronary disease.
Velagapudi P; Turagam MK; Agrawal H; Mittal M; Kocheril AG; Aggarwal K
Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):977-86. PubMed ID: 25046150
[TBL] [Abstract][Full Text] [Related]
14. Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial.
Sherwood MW; Cyr DD; Jones WS; Becker RC; Berkowitz SD; Washam JB; Breithardt G; Fox KA; Halperin JL; Hankey GJ; Singer DE; Piccini JP; Nessel CC; Mahaffey KW; Patel MR
JACC Cardiovasc Interv; 2016 Aug; 9(16):1694-702. PubMed ID: 27539689
[TBL] [Abstract][Full Text] [Related]
15. Prevention of arterial thrombosis by edoxaban, an oral factor Xa inhibitor in rats: monotherapy and in combination with antiplatelet agents.
Honda Y; Kamisato C; Morishima Y
Eur J Pharmacol; 2016 Sep; 786():246-252. PubMed ID: 27288116
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting.
Lacoste JL; Hansen CL
Am J Health Syst Pharm; 2019 Sep; 76(18):1395-1402. PubMed ID: 31505555
[TBL] [Abstract][Full Text] [Related]
17. Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial.
Vanassche T; Verhamme P; Anand SS; Shestakovska O; Fox KA; Bhatt DL; Avezum A; Alings M; Aboyans V; Maggioni AP; Widimsky P; Berkowitz SD; Yusuf S; Connolly SJ; Eikelboom JW; Bosch J
Eur J Prev Cardiol; 2020 Feb; 27(3):296-307. PubMed ID: 31615291
[TBL] [Abstract][Full Text] [Related]
18. A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens.
Providência R; Grove EL; Husted S; Barra S; Boveda S; Morais J
Thromb Res; 2014 Dec; 134(6):1253-64. PubMed ID: 25457584
[TBL] [Abstract][Full Text] [Related]
19. Rivaroxaban 2.5 mg. No justification for using this anticoagulant after an acute coronary syndrome.
Prescrire Int; 2014 Oct; 23(153):229-32. PubMed ID: 25964962
[TBL] [Abstract][Full Text] [Related]
20. Will COMPASS Point to a New Direction in Thrombotic Risk Reduction in Patients With Stable Cardiovascular Disease?
Boden WE; Bhatt DL
Circulation; 2018 Aug; 138(9):858-860. PubMed ID: 30354448
[No Abstract] [Full Text] [Related]
[Next] [New Search]
